Selective Estrogen Receptor Modulators

  • Robert Lindsay


  • Selective estrogen receptor modulators (SERMs) have been developed to find agents that have as many of the beneficial effects of estrogen as possible but without any of the estrogenic side effects.

  • Raloxifene is the first SERM that has been shown to decrease the risk of vertebral fractures in women with postmenopausal osteoporosis.

  • Preliminary data indicate that raloxifene could decrease the risk of breast cancer and cardiovascular events.


Breast Cancer Postmenopausal Woman Vertebral Fracture Menopausal Symptom Selective Estrogen Receptor Modulator 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Further Reading

  1. Barrett-Connor E, Grady O, Sashegyi A, et al. (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. J Am Med Assoc 287: 847–857.CrossRefGoogle Scholar
  2. Delmas PD, Ensrud KE, Adachi JD, et al. (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87: 3609–3617.PubMedCrossRefGoogle Scholar
  3. Ettinger B, Black DM, Mitlak BH, et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 282: 637–645.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2004

Authors and Affiliations

  • Robert Lindsay

There are no affiliations available

Personalised recommendations